Human Aβ1-42 peptide was prepared as a stock solution at a concentration of 1 mg/mL in sterile saline solution, followed by aggregation via incubation at 37 °C for 4 days. The aggregated Aβ1-42 peptide or vehicle (0.9% NaCl, 3 μL/ 5 min/mouse) was stereotaxically administered into the ventricle (i.c.v.) using a Hamilton microsyringe (−0.2 mm anterioposterior (AP), 1 mm mediolateral (ML), and −2.4 mm dorsoventral (DV) to Bregma) under anesthesia in combination with 0.05 mL/100 g body weight Rompun (Xylazine) and 0.1 mL/100 g body weight Zolitil (Ketamine). The rest of the protocol was the same as previously reported76 (link).
Twenty-four hours after Aβ1-42 and vehicle i.c.v. injection, the mice were divided into the following groups: (1) control (C) mice injected i.c.v. with 0.9% saline as a vehicle or i.c.v. with Aβ1-42 (Aβ1-42 group), (2) mice injected with Aβ1-42 and VA 30 mg/kg intraperitoneally (i.p.) for 3 wks (Aβ1-42+ VA), and (3) mice treated with VA 30 mg/kg (i.p.) for 3 wks alone (VA). Twenty-four hours post i.c.v. Aβ1-42 or vehicle injection, VA (30 mg/kg) was administered (i.p.) daily for 3 weeks.
Twenty-four hours after Aβ1-42 and vehicle i.c.v. injection, the mice were divided into the following groups: (1) control (C) mice injected i.c.v. with 0.9% saline as a vehicle or i.c.v. with Aβ1-42 (Aβ1-42 group), (2) mice injected with Aβ1-42 and VA 30 mg/kg intraperitoneally (i.p.) for 3 wks (Aβ1-42+ VA), and (3) mice treated with VA 30 mg/kg (i.p.) for 3 wks alone (VA). Twenty-four hours post i.c.v. Aβ1-42 or vehicle injection, VA (30 mg/kg) was administered (i.p.) daily for 3 weeks.
Free full text: Click here
